Immunovant, Inc. (IMVT)
| Market Cap | 5.89B +130.1% |
| Revenue (ttm) | n/a |
| Net Income | -464.20M |
| EPS | -2.68 |
| Shares Out | 203.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,832,512 |
| Open | 27.79 |
| Previous Close | 27.22 |
| Day's Range | 27.79 - 29.70 |
| 52-Week Range | 13.36 - 30.09 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 33.00 (+14.03%) |
| Earnings Date | May 28, 2026 |
About IMVT
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidia... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price target is $33.0, which is an increase of 14.03% from the latest price.
News
Immunovant price target raised to $32 from $29 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Immunovant (IMVT) to $32 from $29 and keeps a Neutral rating on the shares.
Immunovant price target lowered to $50 from $52 at Leerink
Leerink analyst Thomas Smith lowered the firm’s price target on Immunovant (IMVT) to $50 from $52 and keeps an Outperform rating on the shares. The firm notes the company reported
Morning Movers: Immunovant sinks after batoclimab trials miss goal
Stock futures are lower across the board, reversing the gains that kicked off the second quarter. Markets are giving back yesterday’s relief rally in a sharp sentiment reversal, as geopolitical
Immunovant Transcript: Study result
Brepocitinib's program expands to include a pivotal phase IIb/III trial in lichen planopilaris, targeting a high unmet need with a mechanism well-suited to TH1-driven disease. Batoclimab's phase III TED study missed its primary endpoint, but data support ongoing Graves' disease development and highlight the importance of deep IgG suppression.
Immunovant reports batoclimab clinical studies missed primary endpoint
Immunovant (IMVT) reported the topline results from its two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye diseas...
Immunovant's treatment for eye disease fails late-stage trial
Immunovant said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in a late-stage study.
Bernstein initiates Immunovant with a Market Perform, $28 price target
As previously reported, Bernstein analyst William Pickering initiated coverage of Immunovant (IMVT) with a Market Perform rating and $28 price target The firm says it is a true believer in
Immunovant initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Immunovant (IMVT) with a Market Perform rating and $28 price target
Immunovant price target raised to $23 from $22 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Immunovant (IMVT) to $23 from $22 and keeps a Hold rating on the shares. The firm has updated it model
Immunovant price target raised to $44 from $41 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Immunovant (IMVT) to $44 from $41 and keeps a Buy rating on the shares. The firm adjusted its model following
Immunovant Earnings Call Transcript: Q3 2026
Positive phase 2 results for brepocitinib in cutaneous sarcoidosis highlight strong efficacy and safety, supporting advancement to phase 3. The company remains well-funded with $4.5B in cash and anticipates multiple pivotal readouts and potential launches in 2026.
Immunovant reports Q3 EPS (61c), consensus (70c)
As of December 31, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled $994.5 million, providing runway for announced indications through the potential commercial launch of IMVT-1402 in GD Pub...
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported it...
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and prov...
Immunovant price target raised to $22 from $16 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Immunovant (IMVT) to $22 from $16 and keeps a Hold rating on the shares. The firm updated its model, but
Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
As previously reported, Wolfe Research upgraded Immunovant (IMVT) to Outperform from Peer Perform with a $50 price target. While Graves’ may be an attractive market, the firm had believed re-rating
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research analyst Andy Chen upgraded Immunovant (IMVT) to Outperform from Peer Perform.
Immunovant price target lowered to $41 from $44 at Guggenheim
Guggenheim analyst Yatin Suneja lowered the firm’s price target on Immunovant (IMVT) to $41 from $44 and keeps a Buy rating on the shares following the company’s recent $550M equity
Immunovant Announces Pricing of $550 Million Common Stock Financing
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Immunovant Earnings Call Transcript: Q2 2026
Delivered strong clinical results in DM and Graves' disease, maintained $4.4B cash, and advanced a robust late-stage pipeline. NDA for brepocitinib in DM is on track, with multiple data readouts and launches expected over the next 36 months.
Immunovant reports Q2 EPS (73c), consensus (73c)
As of September 30, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $521.9 million, providing runway for announced indications through GD readout expected in 2027.
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing ...
Immunovant rumor highlighted in Betaville alert
The takeover-focused Betaville blog sent an alert to its subscribers related to a rumor regarding Immunovant (IMVT), sources tell The Fly.
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business ...
Immunovant initiated with a Hold at Truist
Truist initiated coverage of Immunovant (IMVT) with a Hold rating and $16 price target IMVT1402 appears to drive deeper IgG reductions than other FcRn inhibitors, but the firm thinks 1402